Ireland: Matheson Advises On The Sale Of US Biotech Firm Dyax To UK-Listed Shire
Last Updated: 19 November 2015

Matheson advised US biotech firm Dyax on Irish tax matters relating to its US$5.9 billion sale to Shire, the UK-listed pharmaceutical company.  The acquisition is intended to enhance Shire's position in treating rare genetic diseases.

The deal is expected to close in the first half of 2016.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

 
In association with
Press Releases from this Firm
Recent Content from this Firm
By Gearóid Carey
By Garret Farrelly, Nicola Dunleavy, Rhona Henry, Peter O'Brien
By Claire McLoughlin, Karen Reynolds, Darren Maher, Joe Beashel
By Patrick Molloy, Peter O'Brien, Alan Keating, Alma Campion, Rory McPhillips, Laura Gleeson, Donal O'Donovan, Stuart Kennedy, Chris Quinn, William Prentice, Ruth Hunter, Turlough Galvin, Christian Donagh
By Tara Doyle, Michael Jackson, Dualta Counihan, Joe Beashel, Anne-Marie Bohan, Shay Lydon, Liam Collins, Philip Lovegrove, Elizabeth Grace, Oisin McClenaghan, Michelle Ridge, Barry O'Connor, Donal O’Byrne
By Claire McLoughlin, Karen Reynolds
By Tara Doyle, Michael Jackson, Niamh Counihan, Joe Beashel, Anne-Marie Bohan, Shay Lydon, Liam Collins, Elizabeth Grace, Oisin McClenaghan, Michelle Ridge, Barry O'Connor, Donal O’Byrne
By Deirdre Kilroy
By Patrick Molloy, Peter O'Brien, Alma Campion, Rory McPhillips, Stuart Kennedy, Chris Quinn, William Prentice, Ruth Hunter, Turlough Galvin, Christian Donagh, Laura Gleeson, Donal O'Donovan
By Deirdre Kilroy
Tools
Print
Font Size:
Translation
Channels